Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monopar Therapeutics LLC

www.monopartherapeutics.com

Latest From Monopar Therapeutics LLC

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact

Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.

Financing Business Strategies

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Monopar Therapeutics LLC
  • Senior Management
  • Chandler D Robinson, MD, CEO
    Kim R Tsuchimoto, Acting CFO
    Andrew P Mazar, PhD, CSO
  • Contact Info
  • Monopar Therapeutics LLC
    5 Revere Dr.
    Ste. 200
    Northbrook, IL 60062
    USA
UsernamePublicRestriction

Register